Construction of Opa-Positive and Opa-Negative Strains of Neisseria meningitidis to Evaluate a Novel Meningococcal Vaccine

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Sadarangani, Manish ^a,b   Hoe, J Claire ^a   Callaghan, Martin J ^a   Jones, Claire ^a   Chan, Hannah ^c   Makepeace, Katherine ^a   Daniels Treffandier, Hélène ^a   Deadman, Mary E ^a   Bayliss, Christopher ^d   Feavers, Ian ^c   van der Ley, Peter ^e   Pollard, Andrew J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

^e NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; KANAMYCIN; MENINGOCOCCUS VACCINE; OPACITY ASSOCIATED ADHESIN PROTEIN; OUTER MEMBRANE PROTEIN; RECOMBINANT OPACITY ASSOCIATED ADHESIN VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIBODY RESPONSE; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; CONTROLLED STUDY; DNA SEQUENCE; DRUG EFFICACY; FEMALE; GENE AMPLIFICATION; GENE LOCUS; GENE TARGETING; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; NUCLEOTIDE SEQUENCE; OPA GENE; OPAA GENE; OPAB GENE; OPAD GENE; OPAF GENE; PROTEIN EXPRESSION; PROTEIN FUNCTION; SEQUENCE ANALYSIS;

ANIMALS; BACTERIAL OUTER MEMBRANE PROTEINS; IMMUNIZATION; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; MICE; NEISSERIA MENINGITIDIS; RECOMBINANT PROTEINS;

BACTERIA (MICROORGANISMS); MUS; NEISSERIA MENINGITIDIS;

EID: 84871234082     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051045     Document Type: Article

References (77)

1. World Health Organization (1998) Control of epidemic meningococcal disease. WHO practical guidelines. 2nd edition. Geneva, Switzerland: World Health Organization.
2. Finne J, Leinonen M, Makela PH, (1983) Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 2: 355-357.
3. Wyle FA, Artenstein MS, Brandt BL, Tramont EC, Kasper DL, et al. (1972) Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis 126: 514-521.
4. Gray SJ, Trotter CL, Ramsay ME, Guiver M, Fox AJ, et al. (2006) Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit. J Med Microbiol 55: 887-896.
5. Ramsay M, Fox A (2007) EU-IBIS Network. Invasive Neisseria meningitidis in Europe 2006. London: Health Protection Agency.
6. Baethgen LF, Weidlich L, Moraes C, Klein C, Nunes LS, et al. (2008) Epidemiology of meningococcal disease in southern Brazil from 1995 to 2003, and molecular characterization of Neisseria meningitidis using multilocus sequence typing. Trop Med Int Health 13: 31-40.
7. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM, (2001) Meningococcal disease. N Engl J Med 344: 1378-1388.
8. Baker MG, Martin DR, Kieft CE, Lennon D, (2001) A 10-year serogroup B meningococcal disease epidemic in New Zealand: descriptive epidemiology, 1991-2000. J Paediatr Child Health 37: S13-19.
9. Sadarangani M, Pollard AJ, (2010) Serogroup B meningococcal vaccines-an unfinished story. Lancet Infect Dis 10: 112-124.
10. Bonvehi P, Boutriau D, Casellas J, Weynants V, Feron C, et al. (2010) Three doses of an experimental detoxified L3-derived lipooligosaccharide meningococcal vaccine offer good safety but low immunogenicity in healthy young adults. Clin Vaccine Immunol 17: 1460-1466.
11. Keiser PB, Biggs-Cicatelli S, Moran EE, Schmiel DH, Pinto VB, et al. (2011) A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine 29: 1413-1420.
12. Keiser PB, Gibbs BT, Coster TS, Moran EE, Stoddard MB, et al. (2010) A phase 1 study of a group B meningococcal native outer membrane vesicle vaccine made from a strain with deleted lpxL2 and synX and stable expression of opcA. Vaccine 28: 6970-6976.
13. Parkhill J, Achtman M, James KD, Bentley SD, Churcher C, et al. (2000) Complete DNA sequence of a serogroup A strain of Neisseria meningitidis Z2491. Nature 404: 502-506.
14. Tettelin H, Saunders NJ, Heidelberg J, Jeffries AC, Nelson KE, et al. (2000) Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science 287: 1809-1815.
15. Bhat KS, Gibbs CP, Barrera O, Morrison SG, Jahnig F, et al. (1991) The opacity proteins of Neisseria gonorrhoeae strain MS11 are encoded by a family of 11 complete genes. Mol Microbiol 5: 1889-1901.
16. de Jonge MI, Bos MP, Hamstra HJ, Jiskoot W, van Ulsen P, et al. (2002) Conformational analysis of opacity proteins from Neisseria meningitidis. Eur J Biochem 269: 5215-5223.
17. Malorny B, Morelli G, Kusecek B, Kolberg J, Achtman M, (1998) Sequence diversity, predicted two-dimensional protein structure, and epitope mapping of neisserial Opa proteins. J Bacteriol 180: 1323-1330.
18. Gray-Owen SD, (2003) Neisserial Opa proteins: impact on colonization, dissemination and immunity. Scand J Infect Dis 35: 614-618.
19. Virji M, Makepeace K, Ferguson DJ, Achtman M, Moxon ER, (1993) Meningococcal Opa and Opc proteins: their role in colonization and invasion of human epithelial and endothelial cells. Mol Microbiol 10: 499-510.
20. Callaghan MJ, Jolley KA, Maiden MC, (2006) Opacity-associated adhesin repertoire in hyperinvasive Neisseria meningitidis. Infect Immun 74: 5085-5094.
21. Callaghan MJ, Lewis S, Sadarangani M, Bailey SE, Chan H, et al. (2011) Potential of Recombinant Opa Proteins as Vaccine Candidates against Hyperinvasive Meningococci. Infect Immun 79: 2810-2818.
22. Mandrell RE, Zollinger WD, (1989) Human immune response to meningococcal outer membrane protein epitopes after natural infection or vaccination. Infect Immun 57: 1590-1598.
23. Sjursen H, Wedege E, Rosenqvist E, Naess A, Halstensen A, et al. (1990) IgG subclass antibodies to serogroup B meningococcal outer membrane antigens following infection and vaccination. Apmis 98: 1061-1069.
24. Milagres LG, Gorla MC, Sacchi CT, Rodrigues MM, (1998) Specificity of bactericidal antibody response to serogroup B meningococcal strains in Brazilian children after immunization with an outer membrane vaccine. Infect Immun 66: 4755-4761.
25. Bjune G, Hoiby EA, Gronnesby JK, Arnesen O, Fredriksen JH, et al. (1991) Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338: 1093-1096.
26. Sierra GV, Campa HC, Varcacel NM, Garcia IL, Izquierdo PL, et al. (1991) Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 14: 195-207 discussion 208-110.
27. de Moraes JC, Perkins BA, Camargo MC, Hidalgo NT, Barbosa HA, et al. (1992) Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 340: 1074-1078.
28. Noronha CP, Struchiner CJ, Halloran ME, (1995) Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study. Int J Epidemiol 24: 1050-1057.
29. Oster P, Lennon D, O'Hallahan J, Mulholland K, Reid S, et al. (2005) MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 23: 2191-2196.
30. de Jonge MI, Hamstra HJ, Jiskoot W, Roholl P, Williams NA, et al. (2004) Intranasal immunisation of mice with liposomes containing recombinant meningococcal OpaB and OpaJ proteins. Vaccine 22: 4021-4028.
31. Wiertz EJ, Delvig A, Donders EM, Brugghe HF, van Unen LM, et al. (1996) T-cell responses to outer membrane proteins of Neisseria meningitidis: comparative study of the Opa, Opc, and PorA proteins. Infect Immun 64: 298-304.
32. Wiertz EJ, van Gaans-van den Brink JA, Schreuder GM, Termijtelen AA, Hoogerhout P, et al. (1991) T cell recognition of Neisseria meningitidis class 1 outer membrane proteins. Identification of T cell epitopes with selected synthetic peptides and determination of HLA restriction elements. J Immunol 147: 2012-2018.
33. Youssef AR, van der Flier M, Estevao S, Hartwig NG, van der Ley P, et al. (2009) Opa+ and Opa- isolates of Neisseria meningitidis and Neisseria gonorrhoeae induce sustained proliferative responses in human CD4+ T cells. Infect Immun 77: 5170-5180.
34. Lee HS, Boulton IC, Reddin K, Wong H, Halliwell D, et al. (2007) Neisserial outer membrane vesicles bind the coinhibitory receptor carcinoembryonic antigen-related cellular adhesion molecule 1 and suppress CD4+ T lymphocyte function. Infect Immun 75: 4449-4455.
35. Boulton IC, Gray-Owen SD, (2002) Neisserial binding to CEACAM1 arrests the activation and proliferation of CD4+ T lymphocytes. Nat Immunol 3: 229-236.
36. van der Voort ER, van der Ley P, van der Biezen J, George S, Tunnela O, et al. (1996) Specificity of human bactericidal antibodies against PorA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine. Infect Immun 64: 2745-2751.
37. Danner DB, Pifer ML, (1982) Plasmid cloning vectors resistant to ampicillin and tetracycline which can replicate in both E. coli and Haemophilus cells. Gene 18: 101-105.
38. Fisseha M, Chen P, Brandt B, Kijek T, Moran E, et al. (2005) Characterization of native outer membrane vesicles from lpxL mutant strains of Neisseria meningitidis for use in parenteral vaccination. Infect Immun 73: 4070-4080.
39. Hamilton HL, Schwartz KJ, Dillard JP, (2001) Insertion-duplication mutagenesis of neisseria: use in characterization of DNA transfer genes in the gonococcal genetic island. J Bacteriol 183: 4718-4726.
40. Catlin BW, (1960) Transformation of Neisseria meningitidis by deoxyribonucleates from cells and from culture slime. J Bacteriol 79: 579-590.
41. Martin DR, Ruijne N, McCallum L, O'Hallahan J, Oster P, (2006) The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB. Clin Vaccine Immunol 13: 486-491.
42. Rosenqvist E, Hoiby EA, Wedege E, Bryn K, Kolberg J, et al. (1995) Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect Immun 63: 4642-4652.
43. Callaghan MJ, Buckee C, McCarthy ND, Ibarz Pavon AB, Jolley KA, et al. (2008) Opa protein repertoires of disease-causing and carried meningococci. J Clin Microbiol 46: 3033-3041.
44. Virji M, Kayhty H, Ferguson DJ, Alexandrescu C, Heckels JE, et al. (1991) The role of pili in the interactions of pathogenic Neisseria with cultured human endothelial cells. Mol Microbiol 5: 1831-1841.
45. Gomez-Duarte OG, Dehio M, Guzman CA, Chhatwal GS, Dehio C, et al. (1997) Binding of vitronectin to opa-expressing Neisseria gonorrhoeae mediates invasion of HeLa cells. Infect Immun 65: 3857-3866.
46. Virji M, Watt SM, Barker S, Makepeace K, Doyonnas R, (1996) The N-domain of the human CD66a adhesion molecule is a target for Opa proteins of Neisseria meningitidis and Neisseria gonorrhoeae. Mol Microbiol 22: 929-939.
47. Bradley CJ, Griffiths NJ, Rowe HA, Heyderman RS, Virji M, (2005) Critical determinants of the interactions of capsule-expressing Neisseria meningitidis with host cells: the role of receptor density in increased cellular targeting via the outer membrane Opa proteins. Cell Microbiol 7: 1490-1503.
48. Rowe HA, Griffiths NJ, Hill DJ, Virji M, (2007) Co-ordinate action of bacterial adhesins and human carcinoembryonic antigen receptors in enhanced cellular invasion by capsulate serum resistant Neisseria meningitidis. Cell Microbiol 9: 154-168.
49. Virji M, Makepeace K, Ferguson DJ, Watt SM, (1996) Carcinoembryonic antigens (CD66) on epithelial cells and neutrophils are receptors for Opa proteins of pathogenic neisseriae. Mol Microbiol 22: 941-950.
50. Virji M, Evans D, Hadfield A, Grunert F, Teixeira AM, et al. (1999) Critical determinants of host receptor targeting by Neisseria meningitidis and Neisseria gonorrhoeae: identification of Opa adhesiotopes on the N-domain of CD66 molecules. Mol Microbiol 34: 538-551.
51. Weber MV, Claus H, Maiden MC, Frosch M, Vogel U, (2006) Genetic mechanisms for loss of encapsulation in polysialyltransferase-gene-positive meningococci isolated from healthy carriers. Int J Med Microbiol 296: 475-484.
52. Cartwright KA, Stuart JM, Jones DM, Noah ND, (1987) The Stonehouse survey: nasopharyngeal carriage of meningococci and Neisseria lactamica. Epidemiol Infect 99: 591-601.
53. Lorenz MG, Wackernagel W, (1994) Bacterial gene transfer by natural genetic transformation in the environment. Microbiol Rev 58: 563-602.
54. Van Der Ley P, Poolman JT, (1992) Construction of a multivalent meningococcal vaccine strain based on the class 1 outer membrane protein. Infect Immun 60: 3156-3161.
55. Warren MJ, Roddam LF, Power PM, Terry TD, Jennings MP, (2004) Analysis of the role of pglI in pilin glycosylation of Neisseria meningitidis. FEMS Immunol Med Microbiol 41: 43-50.
56. Weynants V, Denoel P, Devos N, Janssens D, Feron C, et al. (2009) Genetically modified L3,7 and L2 lipooligosaccharides from Neisseria meningitidis serogroup B confer a broad cross-bactericidal response. Infect Immun 77: 2084-2093.
57. Gunn JS, Stein DC, (1996) Use of a non-selective transformation technique to construct a multiply restriction/modification-deficient mutant of Neisseria gonorrhoeae. Mol Gen Genet 251: 509-517.
58. Stein DC, (1989) Introduction of cloned genes into Neisseria gonorrhoeae. Clin Microbiol Rev 2 Suppl: S146-149.
59. van der Ley P, van der Biezen J, Poolman JT, (1995) Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer membrane vesicle vaccine. Vaccine 13: 401-407.
60. Kupsch EM, Knepper B, Kuroki T, Heuer I, Meyer TF, (1993) Variable opacity (Opa) outer membrane proteins account for the cell tropisms displayed by Neisseria gonorrhoeae for human leukocytes and epithelial cells. Embo J 12: 641-650.
61. Cohen SN, Chang AC, Hsu L, (1972) Nonchromosomal antibiotic resistance in bacteria: genetic transformation of Escherichia coli by R-factor DNA. Proc Natl Acad Sci U S A 69: 2110-2114.
62. Sambrook J, Russell D (2000) Molecular Cloning. A Laboratory Manual. New York, USA: Cold Spring Harbor Laboratory Press.
63. Norheim G, Arne Hoiby E, Caugant DA, Namork E, Tangen T, et al. (2004) Immunogenicity and bactericidal activity in mice of an outer membrane protein vesicle vaccine against Neisseria meningitidis serogroup A disease. Vaccine 22: 2171-2180.
64. de Jonge MI, Vidarsson G, van Dijken HH, Hoogerhout P, van Alphen L, et al. (2003) Functional activity of antibodies against the recombinant OpaJ protein from Neisseria meningitidis. Infect Immun 71: 2331-2340.
65. Poolman JT, Kriz-Kuzemenska P, Ashton F, Bibb W, Dankert J, et al. (1995) Serotypes and subtypes of Neisseria meningitidis: results of an international study comparing sensitivities and specificities of monoclonal antibodies. Clin Diagn Lab Immunol 2: 69-72.
66. Rosenqvist E, Musacchio A, Aase A, Hoiby EA, Namork E, et al. (1999) Functional activities and epitope specificity of human and murine antibodies against the class 4 outer membrane protein (Rmp) of Neisseria meningitidis. Infect Immun 67: 1267-1276.
67. Welsch JA, Rossi R, Comanducci M, Granoff DM, (2004) Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine. J Immunol 172: 5606-5615.
68. Wedege E (2001) Immunoblot Analysis of Sera from Patients and Vaccinees. In: Pollard AJ, Maiden MC, editors. Meningococcal Vaccines Methods and Protocols. Totowa, New Jersey: Humana Press Inc. pp. 275-288.
69. Hobbs MM, Malorny B, Prasad P, Morelli G, Kusecek B, et al. (1998) Recombinational reassortment among opa genes from ET-37 complex Neisseria meningitidis isolates of diverse geographical origins. Microbiology 144 (Pt 1):: 157-166.
70. Staden R, (1996) The Staden sequence analysis package. Mol Biotechnol 5: 233-241.
71. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, et al. (2007) Clustal W and Clustal X version 2.0. Bioinformatics 23: 2947-2948.
72. Nicholas KB, Nicholas HBJ, Deerfield DWI, (1997) GeneDoc: Analysis and Visualization of Genetic Variation. EMBNEW NEWS 4: 14.
73. Moore J, Bailey SE, Benmechernene Z, Tzitzilonis C, Griffiths NJ, et al. (2005) Recognition of saccharides by the OpcA, OpaD, and OpaB outer membrane proteins from Neisseria meningitidis. J Biol Chem 280: 31489-31497.
74. Borrow R, Carlone GM (2001) Serogroup B and C Serum Bactericidal Assays. In: Pollard AJ, Maiden MC, editors. Meningococcal Vaccines Methods and Protocols. Totowa, New Jersey: Humana Press Inc. pp. 289-304.
75. Hobbs MM, Malorny B, Prasad P, Morelli G, Kusecek B, et al. (1998) Recombinational reassortment among opa genes from ET-37 complex Neisseria meningitidis isolates of diverse geographical origins. Microbiology 144 (Pt 1):: 157-166.
76. Morelli G, Malorny B, Muller K, Seiler A, Wang JF, et al. (1997) Clonal descent and microevolution of Neisseria meningitidis during 30 years of epidemic spread. Mol Microbiol 25: 1047-1064.
77. Maiden MC, Bygraves JA, Feil E, Morelli G, Russell JE, et al. (1998) Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A 95: 3140-3145.